The U.S. Food and Drug Administration announced plans to consolidate its fragmented adverse‑event reporting systems into a single Adverse Event Monitoring System (AEMS). The agency says the unified platform will increase transparency, reduce costs and simplify surveillance across drugs, vaccines and other regulated products. FDA communications stress that AEMS will aggregate reports from legacy systems while enabling more real‑time oversight. Regulatory observers note that AEMS will not change the underlying limitation of spontaneous reports — entries are unverified and cannot by themselves establish causation or true incidence. Still, industry and public‑health stakeholders expect the consolidation to streamline signal detection workflows and reduce duplication across FDA centers.